National News

October concession increase for Risperidone 2mg tablets

PSNC News - 16 November 2018 - 3:00pm

Following further representations from PSNC, there will be an increase to the October 2018 price concession for Risperidone 2mg tablets.

The price concession is now set at £20.00 for a pack of 60 tablets. This revised price will be automatically applied to any prescriptions for Risperidone 2mg tablets submitted in October prescription bundles.

Originally imposed at a price of £1.80 by the Department of Health and Social Care (DHSC), PSNC requested a review of the concessionary price on behalf of community pharmacy contractors.

This concession has been put in place for October 2018 only and announcements about any November concessions will be made in due course.

Please do continue to report supply issues using PSNC’s generic shortages form which can be found here.

 

Categories: National News

Community Pharmacy Northern Ireland (CPNI) campaign

NPA News - 16 November 2018 - 1:58pm
CPNI chief executive Gerard Greene appeared at the recent all party parliamentary group devolved nations evidence session. He described the specific workload and funding pressures in NI and warned that without a new contract, the sector is ‘in crisis’. Further information emerged that several wholesalers have written to Department of Health Northern Ireland to warn “medicines supply will grind to a halt” because of pharmacies’ poor creditworthiness. The NPA is deeply concerned at the financial position of many of our members in Northern Ireland. We encourage all sides to continue talking and explore all potential resolutions to this unprecedented and distressing situation. Meanwhile , we want to remind members in Northern Ireland of the NPA support available to them to help them through financially straightened times: · The NPA Business Efficiency Solutions pack contains information to help with SWOT analysis, GAP analysis, social media and PGD services as well as other resources to help develop new sources of income.…
Categories: National News

Drug Tariff Watch: December 2018 changes

PSNC News - 16 November 2018 - 9:00am

The Preface lists additions, deletions and alterations to the Drug Tariff. Below is a quick summary of the changes due to take place from 1st December 2018.

Part VIIIA additions

Category A

  • Tenofovir 245mg tablets (30)

Category C:

  • Co-trimoxazole 80mg/400mg/5ml solution for infusion ampoules (10) – Aspen Pharma Trading Ltd
  • Dexamethasone 8mg tablets (30) – Teva UK Ltd
  • Dexibuprofen 300mg tablets (60) – Seractil
  • Fondaparinux sodium 1.5mg/0.3ml solution for injection pre-filled syringes (10) – Arixtra
  • Fondaparinux sodium 10mg/0.8ml solution for injection prefilled syringes (10) – Arixtra
  • Fondaparinux sodium 2.5mg/0.5ml solution for injection pre-filled syringes (10) – Arixtra
  • Fondaparinux sodium 5mg/0.4ml solution for injection prefilled syringes (10) – Arixtra
  • Fondaparinux sodium 7.5mg/0.6ml solution for injection pre-filled syringes (10) – Arixtra
  • Gentamicin 20mg/2ml solution for injection ampoules (5) – Wockhardt UK Ltd
  • Gentamicin 5mg/1ml solution for injection ampoules (5) – Gentamicin Intrathecal
  • Glycopyrronium bromide powder for solution for iontophoresis (3g) – AMCo
  • Heparin sodium 5,000units/1ml solution for injection ampoules (10) – Wockhardt UK Ltd
  • Lidocaine 200mg/20ml (1%) solution for injection vials (10) – Hameln Pharmaceuticals Ltd
  • Lidocaine 400mg/20ml (2%) solution for injection vials (10) – Hameln Pharmaceuticals Ltd
  • Liquid paraffin liquid (150ml) – Bell,Sons & Co (Druggists) Ltd
  • Liquid paraffin liquid (2000ml) – J M Loveridge Ltd
  • Liquid paraffin liquid (5000ml) – J M Loveridge Ltd
  • Metronidazole 500mg/100ml infusion 100ml bags (20) – AAH Pharmaceuticals Ltd
  • Morphine sulfate 5mg/5ml solution for injection ampoules (10) – Torbay Pharmaceuticals
  • Octreotide 1mg/5ml solution for injection vials n (1) – Pfizer Ltd
  • Octreotide 50micrograms/1ml solution for injection ampoules (5) – Sandostatin
  • Paracetamol 1g/100ml solution for infusion vials (10) – Accord Healthcare Ltd
  • Phenobarbital 60mg/1ml solution for injection ampoules (10) – Martindale Pharmaceuticals Ltd
  • Sodium bicarbonate 8.4% (1mmol/ml) solution for injection 250ml bottles (10) – AAH Pharmaceuticals Ltd
  • Sodium chloride 30% solution for infusion 100ml vials (10) – Torbay Pharmaceuticals
  • Sodium chloride 30% solution for infusion 50ml vials (10) – Torbay Pharmaceuticals
  • Sodium valproate 300mg/3ml solution for injection ampoules (5) – Episenta
  • Sodium valproate 400mg/4ml solution for injection ampoules (5) – Wockhardt UK Ltd
  • Tenofovir 123mg tablets (30) – Viread
  • Tenofovir 163mg tablets (30) – Viread
  • Tenofovir 204mg tablets (30) – Viread
  • Tobramycin 240mg/6ml solution for injection vials n (1) – Pfizer Ltd
  • Tobramycin 80mg/2ml solution for injection vials n (1) – Nebcin
  • Tobramycin 80mg/2ml solution for injection vials (5) – Pfizer Ltd
  • Tranexamic acid 500mg/5ml solution for injection ampoules (10) – Cyklokapron
  • Triamcinolone hexacetonide 20mg/1ml suspension for injection ampoules (10) – Intrapharm Laboratories Ltd
  • Vancomycin 1g powder for solution for infusion vials (10) – Flynn Pharma Ltd
  • Vancomycin 500mg powder for solution for infusion vials (10) – Flynn Pharma Ltd

Part VIIIA amendments

  • Chloramphenicol 5% ear drops n (10ml) – Martindale Pharmaceuticals Ltd is changing to Category A
  • Clonazepam 500micrograms/5ml oral solution sugar free (150ml) – Rosemont Pharmaceuticals Ltd is changing to Category A
  • Diclofenac sodium 100mg modified-release tablets (28) – Volsaid Retard 100 is changing to Fenactol Retard
  • Diclofenac sodium 75mg modified-release tablets (56) – Volsaid Retard 75 is changing to Fenactol SR
  • Morphine sulfate 10mg/1ml solution for injection ampoules (10) – Wockhardt UK Ltd is changing to Category A
  • Ranitidine 150mg/5ml oral solution sugar free (150ml) – Creo Pharma Ltd is changing to Category A
  • Tobramycin 300mg/5ml nebuliser liquid ampoules (56(4 x n14)) – Tobi is changing to Tymbrineb
  • Ursodeoxycholic acid 300mg tablets (60) – Wockhardt UK Ltd is changing to Category A

Part VIIIA deletions

  • Inositol nicotinate 500mg tablets (100) – Hexopal
  • Inositol nicotinate 750mg tablets (112) – Hexopal Forte

Part IX deletions

It is important to take careful note of removals from Part IX because if you dispense a deleted product, prescriptions will be returned as disallowed.

Product Size, type, product code Snap dressing kit – Gauze All sizes Reusable Pens – AllStar All types and sizes Vacuum Pumps – Owen Mumford Ltd – Rapport Premier SM2200 Leg Bags – L.In.C Medical Systems – LINC-Flo sterile leg bag with lever tap, adjustable inlet tube 350ml bag (LM350AD-L) Belts – AMI Medical Ltd – Suportx Ostomy/Hernia Support Belt All except 15cm depth Colostomy bags – ConvaTec Ltd – Colodress Plus (Stomahesive Wafer) Closed Pouches Opaque and clear starter holes Colostomy bags – ConvaTec Ltd – Esteem Closed Pouches with Integral filter All types and sizes Colostomy bags – ConvaTec Ltd – Esteem+ Closed Pouches with Integral filter X Small – opaque All sizes Ileostomy bags – ConvaTec Ltd – Esteem One-Piece Convex Drainable Pouch with InvisiClose Outlet All types and sizes Pressure plates/shields – Salts Healthcare – Convex Plate for Light White Bag All sizes Pressure plates/shields – Salts Healthcare – Plastic Retaining Shield Single 833008 Two piece ostomy systems – ConvaTec Ltd – Esteem Synergy ileostomy bag S1007F, S1021F, S1212F, S1221F, S1222F and S1231F Two piece ostomy systems – Oakmed Ltd – Option Connect 2 colostomy bag with filter, Clear JH520 Two piece ostomy systems – Oakmed Ltd – Option Connect 2 ileostomy bag with filter, Clear JH220 and JH120

Want to learn more about recent Dispensing & Supply news? Read our monthly updates here.

Categories: National News

Quality Payments: NSAID audit now available

PSNC News - 16 November 2018 - 8:30am

Specialist Pharmacy Service has published the non-steroidal anti-inflammatory drug (NSAID) audit, which community pharmacy contractors will need to complete if they intend to claim for the NSAID quality criterion at the February review point of the Quality Payments Scheme.

Contractors will need to have completed the audit, have notified a patient’s GP where professional concerns are identified, share their anonymised data with NHS England (by submitting this to the NHS Business Services Authority (NHS BSA) who are collecting this information on behalf of NHS England) and have incorporated the learning of the audit into future practice by the review point (15th February 2019) to meet the NSAID quality criterion.

Data must be collected for two weeks with a minimum of ten patients participating in the audit. All patients aged 65 years or over who collect a prescription for any oral NSAID or cyclo-oxygenase-2 (COX2) selective inhibitor (this does not include patients prescribed aspirin) should be included in the audit. In cases where there is difficulty in finding ten patients to participate, the audit should be extended to four weeks after which contractors can submit the data with the number of patients they have if less than ten.

Contractors can choose to enter the data directly onto a web-based platform or use the paper form (a standalone form is available at psnc.org.uk/qpaudit) to collect the data and then transfer the data onto a web-based platform to submit their results to NHS BSA. Two web-based systems are available for the audit; PharmOutcomes* or the NHS BSA Snap Survey.

Having reviewed both systems, PharmOutcomes has the following advantages over the NHS BSA Snap Survey:

  • PharmOutcomes can send an automatic referral letter to a patient’s GP practice (if the NHS BSA Snap Survey is used, contractors will need to manually send this referral letter (a template letter is available at psnc.org.uk/qpaudit);
  • A permanent patient record will be stored on PharmOutcomes; and
  • Contractors will not be required to submit their data once they have entered all their audit data onto PharmOutcomes, the system will automatically do this for contractors (if using the NHS BSA Snap Survey, contractors will need to remember to press the ‘Submit’ button once they have completed all their data entry for this to be submitted to NHS BSA. Failure to submit the data will mean the contractor does not meet the NSAID quality criterion).

*The NSAID audit on PharmOutcomes is freely available to all contractors; PSNC has agreed to use their licence to provide access.

FAQs

Q. When do I need to complete the audit?
Contractors can pick a two-week period between November 2018 and 15th February 2019 to complete the audit; however, contractors are encouraged to not leave completion of the audit until February 2019 in case the data collection period needs to be extended to four weeks if contractors have difficulty in finding ten patients to participate.

Q. Will both of the web-based systems calculate my audit results?
Yes. Both of the web-based systems will calculate a contractor’s results. If PharmOutcomes is used, contractors will be able to access the results in the ‘Reports’ section and can print this off as evidence of meeting the NSAID quality criterion. If the NHS BSA Snap Survey is used and the contractor enters an email address when submitting their results, the contractor will be emailed the results of their audit; this email should be retained as evidence of having met the NSAID quality criterion.

Contractors will, however, need to record how they have incorporated the learning of the audit into future practice elsewhere, as this information cannot be recorded on either of the web-based platforms.

Q. If I have not used PharmOutcomes before, how do I obtain log in details?
If a contractor has not used PharmOutcomes before, log in details can be obtained by sending a message to the PharmOutcomes helpdesk. Contractors will need to provide details of the pharmacy, contact information and an email address to issue the login details to.

Q. Where do I access the NSAID audit on PharmOutcomes?
When you log into PharmOutcomes select ‘Services’; you should see ‘NSAID GI Safety Audit 2018/19’ under the ‘National Audits’ heading.

If you have mislaid your PharmOutcomes login details, visit the Help page.

Categories: National News

Latest European Commission guidance on ‘no deal’ Brexit

NPA News - 15 November 2018 - 4:05pm
The Commission set out several key industries deemed necessary for special, temporary contingency plans to avoid turmoil at borders, at airports and elsewhere. That didn’t include health care, despite concerns having been raised about possible disruption to medicines supply. Instead, the Commission reminded businesses the buck stops with them to prepare for the worst-case scenario. “Contingency measures taken by national or EU authorities cannot replace the preparations that each citizen and business must take to prepare for the United Kingdom’s withdrawal,” the guidance said. “Where new authorizations, licences or certificates will be required, each party has the responsibility to apply in good time,” it added. Regarding medicines, the guidance noted: “The European Medicines Agency (EMA) has conducted several surveys and, where necessary, has contacted holders of EU marketing authorizations to recall the need to take the necessary preparedness measures.” Together with the European Chemicals Agency (ECHA), and others, the EMA has re-attributed regulatory functions from the U.K.…
Categories: National News

Workforce concerns raised in advance of NHS long-term plan

PSNC News - 15 November 2018 - 2:54pm

A report on the NHS workforce published today warns that staff shortages could triple in a decade.

Analysis by the Health Foundation, the King’s Fund and the Nuffield Trust – presented in The health care workforce in England: Make or break? – suggests that the health service could be short of more than 350,000 staff by 2030.

The NHS is struggling to recruit and retain the staff needed to meet rising demand and, if this continues at the same rate, the report argues that it could lead to growing waiting lists and a deterioration in the quality of care provided.

The think tanks propose five key tests, which they say the NHS long-term plan will need to pass:

  1. address workforce shortages in the short term;
  2. address workforce shortages in the long term;
  3. support new ways of working;
  4. address race and gender inequalities in pay and progression; and
  5. strengthen workforce and service planning at all levels of the system.

Under test 3, the report advises that existing healthcare staff should be “contributing at the optimum level of their skill set”, suggesting that “pharmacists can take on medication reviews and some elements of long-term condition management”.

Alastair Buxton, PSNC Director of NHS Services, said:

“We agree that HM Government and NHS leaders need to address the mounting challenges facing the NHS workforce, however the network of over 11,600 community pharmacies are ideally placed to assist. As pressure on the NHS workforce increases, it is more important than ever that we make best use of community pharmacies. There is much more that they could do to help keep people healthy and out of hospitals, in particular by caring for people with long-term conditions, being the first port of call for healthcare advice and acting as health and wellbeing hubs.”

Categories: National News

MHRA Drug Safety Update – November 2018

PSNC News - 14 November 2018 - 2:46pm

Date issued: 14th November 2018

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 12 Issue 4, November 2018) has been published and includes articles on:

  • Hydrochlorthiazide: risk of non-melanoma skin cancer, particularly in long-term use.
  • Systemic and inhaled fluoroquinolones: small increased risk of aortic aneurysm and dissection; advice for prescribing in high risk patients.
  • Support Yellow Card: help improve the safety of medicines in pregnancy and breastfeeding, and in babies and children.

To sdee the latest MHRA Drug Safety Update in full, visit the GOV.uk website.

 

Categories: National News

CPPE Corner: Mary Seacole Leadership Programme for community pharmacy

PSNC News - 14 November 2018 - 2:42pm

Community pharmacists and pharmacy technicians can develop their leadership and management skills with an interactive programme from the Centre for Pharmacy Postgraduate Education (CPPE). We spoke to Lesley Grimes, CPPE lead pharmacist, learning development, to find out more.

Following the success of the first cohorts of the Mary Seacole Leadership Programme for community pharmacy in 2017, we have collaborated with the NHS Leadership Academy to offer the Mary Seacole Leadership programme to pharmacists and pharmacy technicians working in community pharmacy.

Places on the programme are fully funded by the Pharmacy Integration Fund (PhIF). To apply, you need to register for an account with the NHS Leadership Academy and then complete the online registration form.

While some of the cohorts have already been filled, there are still plenty of spaces available in a number of cohorts across the country including:

  • Reading
  • London
  • Liverpool
  • Wimborne (Dorset)
  • Coventry
  • Leeds
  • Nottingham

We have also recently opened up a new cohort in Birmingham that will start on 13th March 2019. The next two cohorts are in Liverpool and Wimborne (Dorset) and the deadlines for applications are on 27th November 2018 and 29th November 2018 respectively.

The Mary Seacole Leadership programme is designed to help you feel more confident in your leadership skills by helping you to identify your strengths and areas for improvement and finding the right style to suit you. The programme is comprised of a six-month interactive online course with support from an online tutor and three compulsory one-day workshops.

On the dedicated Mary Seacole page on the CPPE website, you can find a collection of quotes and video testimonials from participants of the programme, who share their thoughts and experiences.

Categories: National News

NPA: Supreme Court ruling on Pfizer patent a relief

NPA News - 14 November 2018 - 1:18pm
Earlier this morning (Wednesday 14th November 2018) judges ruled against Warner-Lambert, a subsidiary of Pfizer, in its bid to strengthen patent protection of Lyrica and other medicines.   The National Pharmacy Association (NPA) was a respondent in the case. In addition to the NPA, nine other third parties were granted permission to intervene, including the Secretary of State for Health.   The proposals would have meant that if a clinician wrote a generic drug name on a prescription and the pharmacist dispensed the generic product, the pharmacist would be liable for infringement if it transpired the drug had been prescribed to treat a condition covered by the patent.   This would have remained so even if the pharmacist had no knowledge of the patient’s condition, known as the indication, for which the medication was prescribed.   In many circumstances it is not possible to establish the condition of the patient because the prescriber cannot be contacted and patients’ representative, or even the patients themselves, simply do not know.…
Categories: National News

Medical device alert and recall – potential breach in sterile barrier packaging of some products manufactured by ConvaTec Limited

PSNC News - 14 November 2018 - 12:40pm

ConvaTec has voluntarily initiated a recall of specific product codes of Suction Catheters, Gastroenteral Tubes, Intermittent Urology Catheters and sterile Urine Drainage Bags due to the potential breach in sterile barrier packaging. Only the identified product codes and affected lots within this notice may have a potential breach in the sterile barrier packaging.

Action
  • Refer to the manufacturer’s Field Safety Notice FSN for a list of affected product codes and affected lots.
  • Stop using and quarantine affected devices as directed in the manufacturer’s FSN.
  • Complete the ‘Recall Response Form for END USERS’ in the FSN and return to convatecproductrecall@stericycle.com to arrange return of affected device(s).
  • Report any incidents or complaints involving this product to unomedical-uk.customerservice@convatec.com.

 

Date issued: 14th November 2018

MDA number: MDA/2018/034

Affected products: Full list

Manufacturer contacts

ConvaTec Limited Tel: 01244 832206

Recall centre:  convatecproductrecall@stericycle.com

Email: unomedical-uk.customerservice@convatec.com

 

To view the alert please visit the GOV.UK website.

Categories: National News

Christmas opening hours

PSNC News - 13 November 2018 - 5:08pm

Community pharmacy contractors do not have to open on days which are specifically mentioned in the Regulations (namely Christmas Day, Good Friday and Easter Sunday) or a day which has been specifically designated as a ‘bank holiday’, unless directed to open by their local NHS England team.

In December, contractors in England will not be required to open on the following days (unless otherwise directed by their local NHS England team):

  • Christmas Day (25th December 2018)
  • Boxing Day (26th December 2018)

Contractors will also not be required to open on New Year’s Day which falls on Tuesday 1st January 2019.

PSNC’s annual opening hours factsheet provides contractors with a quick reference guide on which public and bank holidays pharmacies can close without giving notice. This is available to download here.

Categories: National News

Class 3 drug alert – Action within five days: Mitomycin-C Kyowa 10mg injection

NPA News - 13 November 2018 - 2:31pm
DRUG ALERT Class 3 drug alert – Action within five days Ref: CLDA (18)A/09 Date 13 November 2018 Product name Mitomycin-C Kyowa 10mg powder for solution for injection (Manufactured by Kyowa Kirin Ltd ) PL 16508/0043 A Class 3 drug alert has been issued by the Medicines & Healthcare products Regulatory Agency (MHRA) for a certain batch of Mitomycin-C Kyowa 10mg Powder for Solution for Injection as stated in the table below: Batch number Expiry date 6058517 June 2019 The above batch has been recalled due to sub visible particles recorded at the 39 month time point; this is an out of specification result. Further information can be found on the MHRA section on the GOV.UK website. Produced by the NPA Pharmacy team November 2018.…
Categories: National News

Mitomycin-C 10mg Powder for Solution for Injection (Kyowa): Company led drug alert

PSNC News - 12 November 2018 - 4:17pm

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a company led drug recall, to be actioned, for certain batches of: Mitomycin-C Kyowa 10mg Powder for Solution for Injection.

Date issued: 12th November 2018

CLDA number: (18) A/09

MDR number: MDR 06-11/18

Batch number: 6058517

The above batch is being recalled because an out of specification result for sub visible particles was recorded at the 39 month time point.

Company contact for stock enquiries:

Martin Smith

Tel: 01896 664030

Email: Martin.Smith@kyowakirin.com

Company contact for medical information enquiries:

Gary Speake

Tel: 01896 664029

Email: Medicalaffairs@kyowakirin.com or Gary.speake@kyowakirin.com

 

To view the alert please visit the GOV.UK website.

 

 

Categories: National News

URGENT (Scotland): The adrenaline auto-injectors 150mcg protocol has been revised with immediate effect

NPA News - 9 November 2018 - 1:51pm
The revised protocol, effective immediately, has been released because current stock levels of AAI are sufficient to ensure that every patient has access at least two AAIs. Due to the backlog of patients awaiting new AAIs, supplies may be limited until the end of 2018. Pharmacists should implement the revised protocol with immediate effect. If in doubt or to check anything, call the NPA Pharmacy team on 01727 891800 — we are available to advise and support you Monday-Friday 9am-6pm and Saturday 9am-1pm For further information please contact the NPA Pharmacy team on 01727 891800 or email at pharmacyservices@npa.co.uk.…
Categories: National News

Review of the funding model in Scotland for Community Pharmacist Supplementary and Independent Prescribing Clinics

NPA News - 9 November 2018 - 10:02am
The NPA called for a new funding model to provide sustainable clinics by including set up, service promotion, pharmacist back fill and administrative time over an adequate period to enable service development.   Please tell us what would enable you to provide/contract an independent or supplementary prescribing service   The National Pharmacy Association Ltd representing our members as independent community pharmacy owners suggest the following criteria is required to enable an independent or supplementary prescribing service to be provided by a community pharmacist Sustainable funding model which enables pharmacist backfill to be arranged and paid fully for each clinic session. This funding should be confirmed at least six months in advance and rolling year to year to enable service development and continuity. The funding should not be dependent on the number of patients seen, as pharmacist clinics in practice often see those patients who frequently “do not attend”  surgery appointments. There should be allotted funding to enable the NHS Board to support the setup of any pharmacist clinic as to standard operating procedures, risk assessment, indemnity costs etc.  …
Categories: National News

Experiential Learning Funding available for Members in Scotland

NPA News - 8 November 2018 - 7:43pm
The Preparation for Facilitating Experiential Learning Training (PFEL) payment is dependent on the training provider having: ·       premises approved by National Education Scotland(NES) ·       commitment to complete specific training e-learning modules ·       attended one day face to face training ·       providing feedback at the end of the placement Access all of the e-modules here. Book training days at https://portal.scot.nhs.uk/ Contact lesley.morrison@nes.scot.nhs.uk to note interest in providing an EL placement this academic year. More information available here.…
Categories: National News

FMD webinar now on-demand

PSNC News - 8 November 2018 - 1:15pm

Community pharmacy contractors can now access an online recording of PSNC’s recent webinar about the Falsified Medicines Directive (FMD).

More than 1,000 people registered for yesterday’s webinar hosted by Alastair Buxton, PSNC’s Director of NHS Services. Alastair used the event to explain how the introduction of FMD will affect the day-to-day working of community pharmacy teams and what they need to do to prepare.

Some of the feedback we have received so far:

“I enjoyed the FMD Webinar. The length of time allocated was just right.” – Pharmacist

“Excellent way of passing the news and educating pharmacists in the UK, thank you very much for your hard work.” – Pharmacy Manager

“Very well presented. Thank you.” – Director/Owner

During the webinar, Alastair described the new processes that FMD will introduce and outlined the guidance and resources developed by the UK FMD Working Group for Community Pharmacy. He also answered a number of viewers’ questions.

With the implementation of FMD now less than three months away (February 2019), this webinar provides contractors and their teams with key actions for them to undertake in advance of that date.

Click here to view an on-demand version of the webinar.*

You can also click here to view the slide pack used in the webinar.

*Please note, to watch the recording, you will need to register (or input the email address you registered with previously).

Categories: National News

URGENT (England): The adrenaline auto-injectors 150mcg protocol has been revised with immediate effect

NPA News - 8 November 2018 - 10:18am
  The revised protocol, effective immediately, has been released because current stock levels of AAI are sufficient to ensure that every patient who presents a prescription will be supplied with at least two AAIs which are in date or have an officially extended expiry date. Due to the backlog of patients awaiting new AAIs, supplies may be limited until the end of 2018.   Pharmacists and their teams should: Read and understand the full contents of the following documents: Interim protocol on dispensing of adrenaline auto-injectors 150microgram “Pharmacy and Dispensing Practice Q&A regarding EpiPen® and EpiPen® Junior Supply issue” Print off the flowchart and ensure that it is readily available in the dispensary Be aware of the officially extended expiry dates on certain lot numbers of Jext 150mcg/300mcg and EpiPen® 300mcg auto-injector Implement the revised protocol with immediate effect If in doubt or to check anything, call the NPA Pharmacy team on 01727 891800 — we are available to advise and support you Monday-Friday 9am-6pm and Saturday 9am-1pm For further information please contact the NPA Pharmacy team on 01727 891800 or email at pharmacyservices@npa.co.uk.…
Categories: National News

PSNC October Meeting: summary for contractors now available

PSNC News - 7 November 2018 - 5:07pm

PSNC’s October meeting was held on the 9th and 10th of the month in Swindon, and key agenda items included:

Download the summary of the October PSNC meeting here.

Further details regarding PSNC’s ongoing work will be shared on the website as soon as possible.

Categories: National News

Millions jeopardise their health by ignoring medicines advice

NPA News - 7 November 2018 - 12:01am
The new survey, by the National Pharmacy Association (NPA), also shows that some people are irritated by the medicines safety protocols in pharmacies and are prepared to fib in order to get around them.   A previous 2018 study¹ found at least 6% of emergency re-admissions to hospital are caused by Adverse Drug Reactions (ADRs). The estimated cost to the NHS of definitely avoidable ADRs is £98.5million per year.   The NPA’s Director of Pharmacy, Leyla Hannbeck, says that talking frankly with a local pharmacist is the best way to understand the risks and benefits of medicines and avoid harm.   She said: “If used inappropriately, medicines have the power to harm as well as to heal, even medicines you can pick up from a supermarket shelf or a pound shop.   “So it’s important to take professional advice, and in particular to have a full and frank dialogue with your local pharmacist.…
Categories: National News
Syndicate content
Continuing Professional Development Just visiting this site means you are probably performing CPD - record it online at www.uptodate.org.uk
Site developed by Gary Warner
Drupal theme by Kiwi Themes.